We’re a little over halfway through 2025, and it’s safe to say this year has seen a lot of movement and shifting policies in the healthcare realm.

So we decided to check in with some execs we spoke with at the beginning of the year about where they’re at with the goals they shared with us. Here’s what they had to say.

These interviews have been lightly edited for length and clarity.

Brian Evanko, president and COO, the Cigna Group

The first half of 2025 has proven that the US healthcare system remains highly dynamic, and we continue to innovate and evolve rapidly to meet the needs of our customers, clients, clinician partners, and all those we serve. We’ve accelerated our work to leverage data, advanced analytics, and emerging AI capabilities to improve our customers’ experiences as part of our “Commitment to Better” [initiative] launched earlier this year, and we just announced an AI-powered virtual assistant and a suite of other digital features to help Cigna Healthcare customers navigate their healthcare more easily. These are just examples of the actions we are taking to make healthcare simpler, more personalized, and more technologically enabled. We still have work to do, but I am proud of the progress we are making.

Here’s what execs had to say.—NO

Welcome back to AI 411, a monthly roundup of artificial intelligence (AI) announcements from across the healthcare industry.

This month, the FDA announced the launch of a large language model (LLM) AI tool named Elsa. In a press release on its website, the FDA said that Elsa is designed to “summarize adverse events to support safety profile assessments, perform faster label comparisons, and generate code to help develop databases for nonclinical applications.” It marks the agency’s first step in its AI journey.

But that wasn’t the only news this June. Here’s your roundup of health-related AI updates from around the industry.

American Medical Association (AMA). On June 11, the AMA adopted a new policy calling for “explainable clinical AI tools” that give users clear information about the safety and efficacy of the product. In other words, the AMA is asking AI tool companies to provide clear explanations of how their tools work so clinicians can make the best decisions when using them.

See the full list here.—CM

Continuous glucose monitors (CGMs) have long been recommended to help patients manage treatment for diabetes.

But in recent years the medical tools have caught the attention of a larger cohort of folks who are interested in carefully tracking how certain behaviors, such as eating and exercising, can affect their overall health.

Roblox CEO David Baszucki admitted he was hooked on the wellness trend during an April interview with Fortune, telling the outlet he wears a CGM to track his sugar intake “at times,” adding, “I highly recommend CGMs for everyone.”

Now Baszucki—who also invests in research tied to this trend—is working on evangelizing his own employees to be CGM converts. He recently announced on X that Roblox would cover a one-month CGM subscription for employees, along with one-on-one health coaching sessions.

Keep reading here on HR Brew.—CV